Corporation
Pharmascience Inc.
- Meetings this Parliament
- 175
- With MPs
- 20
- Since Nov 2021
- 212
- Active registrations
- 1
Most recent reported meeting: Oct 13, 2026.
Lobbying by Pharmascience Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Oct 20, 2026 Receives government funding
Filed by David Goodman, Chief Executive Officer
Lobbyists
- David Goodman · Executive Chairman
- Julie Seïde · Director, Government Affairs
- Ken Gagnon · Senior Manager, Government Affairs
- Morris Goodman · Co-Founder
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Transport Canada (TC)
What they're lobbying on (8)Hide details
- Policies aimed at reinforcing pharmaceutical supply chain.
- Discussion regarding the launch of new branded product in the rare disease space
- Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
- Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
- Policies aimed at facilitating generic drug repurposing.
- Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
- Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
- Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Registration 725814-234102-38. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by David Goodman (205), Martin Arès (7).
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Mike McGuire · Directeur général, Politiques internationales et frontalières, Public Safety Canada (PS)
- Philippe Roseberry · Directeur, Politiques frontalières, Public Safety Canada (PS)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Carlos Leitão · Député
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Jennifer Lutfallah · Vice-présidente de la Direction générale du secteur commercial et des échanges commerciaux, Canada Border Services Agency (CBSA)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Aaron Fowler · SMA associé pour le commerce international et négociateur commercial en chef, Global Affairs Canada (GAC)
- David Hutchinson · Director General at Global Affairs Canada, Global Affairs Canada (GAC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Celia Lourenco · Sous-ministre adjointe déléguée, Health Canada (HC)
- Joyce Boye · Directrice générale, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Cloé Tourigny · Parliamentary Intern to Helena Jaczek, House of Commons
- François Rémillard · Parliamentary Assistant to Jacque Ramsey, House of Commons
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Helena Jaczek · Députée
- Jacques Ramsay · Député
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Philip Jennings · Sous-ministre, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Greg Orencsak · Sous-ministre, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Karim Bardeesy · Député
- Paul Moen · Chef de cabinet, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Michael Hahn · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Mackenzy Metcalfe · Conseillère en politiques, Finance Canada (FIN)
- Élyse Moisan · Conseiller politique, Finance Canada (FIN)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Jean-Francois Courtois · Directeur exécutif, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
- Alison McConnell · Directrice adjointe, Innovation, Science and Economic Development Canada (ISED)
- Nadeen abd el aal · Analyste princ. de politiques, Innovation, Science and Economic Development Canada (ISED)
and 1 moreShow fewer
- Inga Pusca · Gestionnaire princ. d'investissements p. int., Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Mark Carney · Premier ministre, Prime Minister's Office (PMO)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Marjorie Michel · Ministre, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Mackenzy Metcalfe · Conseillère en politiques, Finance Canada (FIN)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Sandenga Yeba · Deputy chief of staff and policy director, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Nadeen Abd El Aal · Analyste princ. de politiques, Innovation, Science and Economic Development Canada (ISED)
- Inga Pusca · Gestionnaire princ. d'investissements p. int., Innovation, Science and Economic Development Canada (ISED)
- Jean-Francois Courtois · Directeur exécutif, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
and 1 moreShow fewer
- Alison McConnell · Diretrice adjointe, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.